Drugs · acquisition-cost intelligence
Mounjaro
tirzepatide· ingredient tirzepatideOther blood glucose lowering drugs, excl. insulins· TIRZEPATIDE 10 mg/.5mL; TIRZEPATIDE 12.5 mg/.5mL; TIRZEPATIDE 12.5 mg/mL; TIRZEPATIDE 15 mg/.5mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$526.31
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.